Equities research analysts expect Sientra, Inc. (NASDAQ:SIEN) to announce $17.90 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Sientra’s earnings, with the highest sales estimate coming in at $18.10 million and the lowest estimate coming in at $17.50 million. Sientra posted sales of $19.22 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 6.9%. The company is scheduled to report its next earnings report on Monday, November 8th.
According to Zacks, analysts expect that Sientra will report full year sales of $78.57 million for the current financial year, with estimates ranging from $76.50 million to $82.00 million. For the next fiscal year, analysts expect that the company will report sales of $96.50 million, with estimates ranging from $92.50 million to $99.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Sientra.
Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Tuesday, August 10th. The medical instruments supplier reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.13). Sientra had a negative net margin of 119.58% and a negative return on equity of 901.29%.
In related news, CEO Ronald Menezes acquired 5,800 shares of Sientra stock in a transaction that occurred on Thursday, August 12th. The stock was bought at an average price of $6.98 per share, with a total value of $40,484.00. Following the transaction, the chief executive officer now directly owns 505,800 shares in the company, valued at $3,530,484. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Oliver Christian Bennett sold 3,615 shares of the stock in a transaction on Friday, August 20th. The stock was sold at an average price of $6.93, for a total value of $25,051.95. Following the completion of the sale, the insider now directly owns 80,483 shares in the company, valued at $557,747.19. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 8,698 shares of company stock valued at $59,002. 1.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in SIEN. Point72 Hong Kong Ltd bought a new position in Sientra in the 1st quarter valued at approximately $33,000. Metropolitan Life Insurance Co NY increased its holdings in shares of Sientra by 45,920.0% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 6,903 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 6,888 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Sientra in the first quarter worth $75,000. Amalgamated Bank bought a new position in shares of Sientra during the second quarter valued at $84,000. Finally, Atom Investors LP purchased a new stake in shares of Sientra during the first quarter valued at $115,000. 88.81% of the stock is owned by institutional investors.
Shares of NASDAQ:SIEN traded up $0.03 on Tuesday, hitting $6.07. The company had a trading volume of 430,695 shares, compared to its average volume of 896,049. The firm’s 50-day simple moving average is $7.02 and its two-hundred day simple moving average is $7.12. The firm has a market capitalization of $352.04 million, a price-to-earnings ratio of -3.19 and a beta of 2.12. Sientra has a 1 year low of $3.21 and a 1 year high of $9.14.
Sientra, Inc operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM.
Recommended Story: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.